' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.
Oeller, M; Laner-Plamberger, S; Krisch, L; Rohde, E; Strunk, D; Schallmoser, K;
Int J Mol Sci. 2021; 22(10):
Übersichtsarbeiten

PMU-Autor/inn/en

Krisch Linda
Laner-Plamberger Sandra
Öller Michaela
Rohde Eva
Schallmoser Katharina
Strunk Dirk

Abstract

Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.


Find related publications in this database (Keywords)

regeneration
human platelet lysate (HPL)
good manufacturing practice (GMP)
cell therapy
platelet concentrates
regenerative medicine